2. Orientation Schedule – Day 1
Time Topic Facilitator
9:00 AM Breakfast and AVEO Overview Senior Management
9:45 AM AVEO Day-to-Day Resources Tracey Janesheski, HR Associate
10:00 AM Keeping the Workplace Safe Safety
10:15 AM Your AVEO Benefits & EE Photo Jaimie Mailander, HR Associate
12:00 PM Lunch Hiring Manager
2nd Day
9:30 AM
Quality Assurance Orientation
Within 1st 60 Days
Check-In with Your HR Business
Partner
Within 1st 60 Days Legal Orientation Joe Vittiglio, Senior VP & General Counsel
2
7/17/2013 2 CONFIDENTIAL
4. 4
The AVEO Executive Committee
From top left corner: Tuan Ha-Ngoc, Jeno Gyuris, Murray Robinson, David Johnston.
Seated, from left: Elan Ezickson, Michael Bailey, Nell Jones, Joseph Vittiglio, Bill Slichenmyer
7/17/2013 4 CONFIDENTIAL
5. Tuan Ha-Ngoc
President/CEO
Joseph Vittiglio
Sr. VP & General
Counsel
-Intellectual
Property
Nell Jones
Sr. VP, Human
Resources
Elan Ezickson
Executive VP &
COO
-Medical Affairs
-Technical Operations
-Program & Alliance
Management
Michael Bailey
Chief Commercial
Officer
Commercial &
Marketing
Jeno Gyuris
CSO
-Translational Research
-Preclinical
Development
-Bioinformatics
David Johnston
CFO
-Finance
-Investor Relations
-Facilities
-IT
Bill Slichenmyer
CMO
-Clinical
-Pharmacovigilance
-Biometrics
-Regulatory Affairs
Carole Varanelli
VP Quality
Rob Kloppenberg
VP, Corp. Comm.
& Public Affairs
The AVEO Organization
6. CLINICAL ACTIVITIES
AND PIPELINE DEALS
HRP AND HRP DEALS
MERGER OF HRP &
PRODUCTS/CLINICAL
PROGRAMS
SERIES A SERIES B SERIES C SERIES D SUCCESSFUL IPO PIPE FOLLOW-ON
TIVOZANIB PH 2 RCC
STUDY INITIATED
FICLATUZUMAB PH 1
INITIATED
AVEO REGAINS
RIGHTS TO
FICLATUZUMAB
TIVO-1
INITIATED FICLATUZUMAB
PH 2 NSCLC INITIATED
BATON-RCC
BATON-CRC
2002-2012: A Decade of Delivery
2002 | | | | | 20126
7. Human Response Platform™: Insights into Cancer Biology
7/17/2013 CONFIDENTIAL7
U.S. Patent No. 6,639,121 Issued in 2003
Discovery and
validation of
functionally relevant
targets
Maturing pipeline of
novel functional
antibodies
Biomarker-driven
identification of responsive
patient populations
Genetic signatures of tumors
informs rational choice of drug
combinations
Biomarker data provides
opportunity to optimize
benefits in selected patients
Supports pricing and
reimbursement
8. Building A Sustainable Pipeline
7/17/2013 CONFIDENTIAL8
= FOUNDATION FOR BIOMARKER CLINICAL STATEGIES
*Aveo and Astellas Pharma Inc. have a worldwide agreement to co-develop and commercialize tivozanib outside of Asia
**Anti-ErbB3 program is strategically partnered with Biogen Idec
10. RCC market valued at $2B WW1
Despite advances, unmet medical need persists2
Tivozanib: Potential Standard of Care in First-Line RCC
• Current therapies provide less than
12 months of first-line PFS and
therefore there remains a significant
unmet need2
• Reducing the dosage or delaying
treatment of therapies due to AEs
(fatigue, diarrhea and hand-foot
syndrome) is a major limitation2
• Many patients cannot tolerate
current therapies for a long period of
time, impacting potential to achieve
maximal efficacy2
7/17/2013 CONFIDENTIAL10
1. Wolters Kluwer and IMS Health
2. Campbell Alliance interviews with 7 KOLs. Aug, 8 through Aug. 12, 2011.
Improved Efficacy
Improved Safety
and Tolerability
11. 7/17/2013 CONFIDENTIAL
TIVO-1 Top-Line: Statistically Significant Superiority
• Well-tolerated safety profile consistent with Phase 2
– Hypertension was most common side effect; on-target class effect and
manageable
– Phase 2 experience:
• Low rate of dose reductions and interruptions, and serious side effects (grade 3/4)
• Hypertension and dysphonia most commonly reported side effects;
both mechanism-related, manageable and reversible
• Side effects commonly associated with other VEGFR inhibitors (diarrhea, fatigue
and hand-foot syndrome) were notably low
11
SAFETY
EFFICACY
Median PFS / Treatment Naïve (70% of overall)
Tivozanib 12.7 months
Sorafenib 9.1 months
Median PFS / Overall Study
Tivozanib 11.9 months
Sorafenib 9.1 months
12. Our Total Approach to Patient
7/17/2013 CONFIDENTIAL12
Access
Disease
Management
AdvocacySupport
Predictive
Biomarkers
Efficacy Tolerability
13. Partnership with Astellas
• In February 2011, AVEO and Astellas entered into a worldwide
agreement outside of Asia to develop and commercialize tivozanib
for the treatment of a broad range of cancers.
Astellas, located in Tokyo, Japan, is a pharmaceutical company
with approximately 16,800 employees worldwide
• AVEO will be responsible for the manufacturing of tivozanib and
lead commercialization in North America
• Astellas will lead commercialization in the European Union
• AVEO and Astellas plan to jointly conduct and fund the expansion
of tivozanib clinical development into additional solid tumor types.
CONFIDENTIAL13
7/17/2013
14. Where We are Today
• 220+ employees
• US and EU field presence (Germany, UK, France)
14
Cambridge, MA
7/17/2013 14 CONFIDENTIAL
Windsor, UK
15. AVEO Clinical Trial Sites and MSL Locations
CONFIDENTIAL15
7/17/2013
RCC KOL Location
CCC Location
Current MSL
Location
18. New Hire Resources on the AVEO Insider
18http://aveo/metadot/index.pl?id=3139&isa=Category&op=show
7/17/2013 18 CONFIDENTIAL
19. 7/17/2013 CONFIDENTIAL19
AVEO Policies
• AVEO employees are required to read and acknowledge receipt
of the following Company policies
– Non-Discrimination & Non-Harassment
– Time Away From Work
– Electronic Communications & Info Systems
– Family & Medical Leave Act
– Laboratory Notebook Policy
– Insider Trading
– Disclosure Policy
– Written Comprehensive Information Security Program (WISP)
• May be required if as part of your position you have access to certain sensitive information
– Overtime and Holiday Policy
• Required only if you are an hourly, or non-exempt, employee
21. 2012 Summer Events : 10th Anniversary Year
7/17/2013 CONFIDENTIAL21
• Celebration at Fenway Park
• Guided tour, dinner, AVEO apparel
• Prouty Ride to benefit the Norris Cotton
Cancer Center
• Second Quarter all company meeting &
poster session
• Day of Community Service
• Corporate Donation of $10,000 in the
name of all employees to the Jimmy
Fund
JULY 17, 2013 CONFIDENTIAL21
22. The AVEO Way: Putting the Patient First
7/17/2013 22 CONFIDENTIAL
AVEO Oncology is…
…passionate in our pursuit of improving the lives of cancer patients…
…powered by innovation…
…supportive of a creative and collaborative culture…
…committed to creating value for our shareholders.
This is the AVEO Way – the Human Response.
23. AVEO Rewards and Recognition Program
• Annual CEO Award - $5,000
• Executive Team Award - $500
• Team Award - $150 AmEx Gift Card
• Spot Award (Individual) - $150 AmEx Gift Card
• Thanks Award - $25 AmEx Gift Card
AVEO’s CEO Award
Recipients:
2012 – Andrew Strahs, Sr. Director,
Biometrics
7/17/2013 23 CONFIDENTIAL
24. Connect with Your AVEO Ambassador
• Ambassadors are employees at all levels who:
– Know the culture
– Know how to get things done
– Convey practical knowledge
• Your Ambassador will help you navigate our campus and culture for the first
30 days
24
7/17/2013 24 CONFIDENTIAL
History – what has happened over 10 years462 companies started in the US around when we started 10 years ago. 302 still in business. 6 with positive phase 3 NCEs going to market (including us). AVEO has entered into multiple types of strategic partnership arrangements with several leading pharmaceutical and biotech companies:12/2006 In-licensing of tivozanib (Kyowa Hakko Kirin Pharma)3/2009 Exclusive option agreement for anti-ErbB3 program (Biogen Idec)12/2010Funded research collaboration and application of AVEO’s proprietary technology platform (OSI Pharmaceuticals now a wholly-owned subsidiary of Astellas US Holding)5/2011 Exclusive license agreement for worldwide development and commercialization of AVEO’s RON-targeted antibodies (Centocor Ortho Biotech)2/2011 Worldwide agreement to co-develop and commercialize lead product candidate, tivozanib, outside of Asia (Astellas Pharma Inc.)AVEO and Astellas have initiated the BATON (Biomarker Assessment of Tivozanib in ONcology) program, a series of clinical trials assessing tivozanib biomarkers in solid tumors.Funding of companyIPO in March of 2010NASDAQ
AVEO is drawing on its deep understanding of cancer biology to advance oncology care with next generation products. The insights gained from our proprietary discovery engine, the Human Response Platform, enable AVEO to develop medicines to treat patients who share molecular subtypes of cancer and meet their unique clinical needs. How: BYIdentifying and validating which of the many candidate cancer causing genes are most important to tumor growth.Enabling the development of tumor models driven by the target gene of interest to facilitate the evaluation of drug candidates directed against the targetEnabling the identification of genetic markers, or biomarkers that may help identify patients more likely to be responsive or resistant to such drugs
May 2012AV 203 Phase 1 dose escalation safety study initiated at MD AndersonJune 2012Initiation of the TAURUS patient preference Phase2 study comparing tivo vs. sunitinibOctober 1, 2012ESMO presentation on the Ficla Phase 2 – study identified potential predictive biomarkers for patients with advanced NSCLCDec 2012Phase 2 clinical trial, BATON-BC evaluating the efficacy of tivowoithpaclitaxel compared to placebo (Biomarker Assesment of Tivo in Oncolcogy)
TIVO is a potent and selective inhibitor of all three VEGF receptors. These are vascular endothelial growth factor Tivozanib: Lead Product Candidate for First-Line Therapy for Advanced RCC Advanced RCC, or kidney cancer, is the ninth most commonly diagnosed cancer in men and women in the U.S.1 Worldwide it is estimated that more than 250,000 people are diagnosed and more than 100,000 people die from the disease each year2.RCC accounts for 90 percent of all malignant kidney tumors3. Despite advances in RCC therapies, significant unmet need persists.
Mention Market size
tivozanib demonstrated a statistically significant improvement in PFS with a median PFS of 11.9 months compared to a median PFS of 9.1 months for sorafenib in the overall study populationtivozanib demonstrated a statistically significant improvement in PFS with a median PFS of 12.7 months compared to a median PFS of 9.1 months for sorafenib in the pre-specified subpopulation of patients who were treatment naïve (no prior systemic therapytivozanib demonstrated a well-tolerated safety profile the most commonly reported side effect was hypertension, a well established on-target and manageable effect of VEGFR inhibitors
Our approach will be a market differentiator for AVEO
(Kyowa Hakko Kirin retains the rights to develop and commercialize tivozanib in Asia )
AVEO Oncology is passionate in our pursuit of improving the lives of cancer patients. We are united in our efforts to provide patients with reasons to believe that they can receive effective treatments while carrying on with their daily living. The Human Response is more than a novel biology platform – it is our way of responding to needs of the cancer community with integrity, fierce determination, and compassion. AVEO Oncology is powered by innovation and founded on a unique drug discovery and development approach called the Human Response Platform. We will translate cancer biology insights into next generation therapeutics targeted to specific patients living with cancer who will benefit most. AVEO Oncology is supportive of a creative and collaborative culture where our employees’ personal growth and professional development are a priority. AVEO Oncology is committed to creating value for shareholders, ensuring financial resources that allow us to achieve our mission. This is the AVEO Way, the Human Response. AVEO Sponsors the MGH Cancer Center Gala - The One Hundred with a $10,000 donation Prouty 2012 Silver Wheel Corporate Sponsor of $15,000Corporate Donation of $10,000 in the name of each employee to the Jimmy Fund
